Mount Sinai Health System Launches COVID-19 Saliva Testing Program to Protect Public Health as Business and Leisure Activities Reopen

April 5, 2021

As businesses look for ways to safely reopen, Mount Sinai Health System announced today the launch of the Mount Sinai COVID-19 PCR Saliva Testing program to provide quick, noninvasive, and precise testing to support safety for businesses and leisure activities in New York.

The Program offers an easy, effective, and accurate COVID-19 test for the public. Mount Sinai is an official partner of the New York State Excelsior Pass program, a new effort to fast-track the opening of theaters, stadiums, and other businesses.

Using advanced laboratory technology that detects the presence of the virus that causes COVID-19 in saliva, the Mount Sinai program guarantees final results within 48 hours, although the vast majority of results return within 24 hours. The program offers four convenient testing locations in Manhattan: Mount Sinai Business Health at 226 West 14th Street, Mount Sinai Doctors at Health Quarters Noho at 632 Broadway, Mount Sinai Doctors at 55 East 34th Street, and Mount Sinai Express Care at 1190 Fifth Avenue. Results are transmitted securely and rapidly to the Excelsior Pass app, allowing ease of admission to venues that use the app, such as theaters and stadiums.

“Mount Sinai has shown extraordinary commitment and leadership in scientific and clinical efforts to beat this pandemic. We developed one of the first highly sensitive antibody tests, pioneered innovative therapies to treat COVID-19, and are researching the lingering effects suffered by ‘long-haulers.’ This program is designed to help our community in slowing transmission and getting us back to normal,” said David L. Reich, MD, President and Chief Operating Officer, The Mount Sinai Hospital. “The Mount Sinai program will make testing more accessible and convenient so as to protect public health. We are proud to partner with New York State and to be a provider of choice for testing.”

Mount Sinai’s saliva test is an easy, safe, and accurate alternative to the more commonly used nasal and nasopharyngeal swab tests but uses the same, highly accurate polymerase chain reaction (PCR) technology. It can also be administered to young children. If a saliva sample cannot be obtained, or if someone has eaten or drunk something prior to the test, a nasal swab test can be performed instead. The test can also be used for business or leisure travel purposes or return-to-work authorization. To schedule an appointment, visit https://www.mountsinai.org/lp/covid19-saliva-test.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version